The prognosis for patients taking lenalidomide can vary but has generally improved the outcomes for many with multiple myeloma and other cancers. In multiple myeloma, it has been shown to extend progression-free survival and overall survival, especially when used as part of combination therapy. In MDS, it has helped many patients reduce their dependence on blood transfusions.
